The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts
Release Date: February 2015
Number of Pages: 249
Number of Tables and Figures: 54
Synopsis: A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.
Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.
SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.
The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a sample of the report or any further inquiries please contact email@example.com
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
Company Wide License (Global Site): USD 6,500
The report has the following key findings:
- Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
- As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
- In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
- In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
- Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.
The report covers the following topics:
- Generic drugs ecosystem
- Market drivers and barriers
- Technology, economics and key trends
- Pure, branded and super generics
- Analysis of key therapeutic areas and leading generic drugs
- Regulatory landscape of generic drugs throughout the globe
- Industry roadmap and value chain
- Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers
- Strategic recommendations for ecosystem players
- Market analysis and forecasts from 2015 till 2030
Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
- Brand Classification
- Pure (Non-branded) Generics
- Branded Generics
- Super Generics
- Therapeutic Area
- Cardiovascular & Hypertension
- CNS (Central Nervous System)
- Hormonal Drugs
- Pain Relief
- Regional Markets
- Asia Pacific
- Middle East & Africa
- North America
- Latin & Central America
- Country Markets
- Saudi Arabia
- South Africa
- South Korea
Key Questions Answered:
The report provides answers to the following key questions:
- How big is the generic drugs opportunity?
- What trends, challenges and barriers are influencing its growth?
- How is the ecosystem evolving by segment and region?
- What will the market size be in 2020 and at what rate will it grow?
- Which countries and submarkets will see the highest percentage of growth?
- How big is the market for generic cancer drugs?
- How does regulation impact the adoption of generic drugs?
- How will branded and super generics impact revenue prospects?
- Who are the key market players and what are their strategies?
- How will patent expirations of biologics impact the market?
- What are the future prospects of approved and non-approved biosimilar drugs?
- What strategies should generic and innovator drug manufacturers adopt to remain competitive?
List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
AMA (African Medicines Regulatory Agency)
AMRI (Albany Molecular Research, Inc.)
ASKA Pharmaceutical Company
BD (Becton, Dickinson and Company)
BMS (Bristol-Myers Squibb)
BPI (Breckenridge Pharmaceutical Inc.)
Cadila Healthcare (Zydus Cadila)
CBER (Centre for Biologics Evaluation and Research)
CDER (Centre for Drug Evaluation and Research)
CDSCO (Central Drug Standards and Control Organization, India)
CFDA (China Food and Drug Administration)
Chugai Pharmaceutical Company
Daiichi Sankyo Espha
Dr. Reddy's Laboratories
EGA (European Generic Medicines Association)
Eli Lilly and Company
Elmed Eisai Company
EMA (European Medicines Agency)
FDA (Food and Drug Administration)
Fuji Pharma Company
Fujifilm Holdings Corporation
Fujifilm Pharma Company
Gedeon Richter PregLem
GGL (Glenmark Generics Limited)
Guangdong BeiKang Pharmaceutical Company
Hanmi Pharmaceutical Company
JHP Group Holdings
Johnson & Johnson
JT (Japan Tobacco)
Kaken Pharmaceutical Company
Kowa Health Care America
Kowa Pharmaceuticals America
Kowa Research Institute
Kremers Urban Pharmaceuticals
Krka (Krka, d. d.)
Kyowa Hakko Kirin Company
Kyowa Pharmaceutical Industry Company
Les Laboratoires Servier
Lundbeck (H. Lundbeck A/S)
Meiji Seika Pharma Company
Merck and Co.
Ministry of Health, Labour and Welfare (Japan)
Mitsubishi Chemical Holdings Corporation
Mitsubishi Tanabe Pharma
Mitsui & Company
MN (Mustafa Nevzat) Pharma
Nichi-Iko Pharmaceutical Company
Nipro Pharma Corporation
Ono Pharmaceutical Company
Osaka Synthetic Chemical Laboratories
Otsuka Holdings Company
Otsuka Pharmaceutical Company
Par Pharmaceutical Companies
Pierre Fabre (Laboratoires Pierre Fabre)
Pliva (Pliva d.d.)
Qualitest and Vintage Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
Sanofi-Aventis Nichi-Iko K.K.
Santen Pharmaceutical Company
Sawai Pharmaceutical Company
Shionogi & Company
Somar (Grupo Farmaceutico Somar)
Sumitomo Dainippon Pharma Company
Sun Pharmaceutical Industries
Supera Farma Laboratorios
Taisho Pharmaceutical Company
Taisho Pharmaceutical Holdings Company
Taisho Pharmaceutical Industries
Taiyo Pharmaceutical Industry Company
Takeda Pharmaceutical Company
Tanabe Seiyaku Hanbai Company
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
Teva-Kowa Pharma Company
The Medicines Company
Towa Pharmaceutical Company
United Therapeutics Corporation
Valeant Pharmaceuticals International
Ventana Medical Systems
WHO (World Health Organization)